Pulse Biosciences presents clinical data from nPulse Cardiac Catheter System

Pulse Biosciences (PLSE) announced late-breaking “positive” clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. Key study findings on the 5 second ablation cohort include: Sustained 100% procedural success of evaluable patients by holter at 6 months; Sustained 96% procedural success of evaluable patients by holter at one year; Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year; Consistently efficient procedural performance, including: Left atrial dwell time: 18.6 +/- 13.0 minutes, Total procedure time: 60.2 +/- 27.7 minutes, Fluoroscopy time: 9.4 +/- 5.9 minutes, Average applications per-patient for PVI: 12.3 +/- 2.6; Safety profile across total cohort: maintained low serious adverse event rate, with 1.7% of subjects experiencing a SAE related to the primary safety endpoint